Protagenic Therapeutics, Inc.\new annual net income
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Net Income Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's net income was $1.4M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.4M | $5.0M | — |
| 2025 | 2025-03-31 | −$3.6M | — | — |
| 2024 | 2024-12-31 | −$5.5M | −$524,847 | — |
| 2023 | 2023-12-31 | −$5.0M | −$1.4M | — |
| 2022 | 2022-12-31 | −$3.6M | $967,429 | — |
| 2021 | 2021-12-31 | −$4.5M | −$2.0M | — |
| 2020 | 2020-12-31 | −$2.5M | −$797,824 | — |
| 2019 | 2019-12-31 | −$1.8M | $806,620 | — |
| 2018 | 2018-12-31 | −$2.6M | −$297,895 | — |
| 2017 | 2017-12-31 | −$2.3M | $16,190 | — |
| 2016 | 2016-12-31 | −$2.3M | −$1.3M | — |
| 2015 · Dec 31 | 2015-12-31 | −$1.0M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$476,000 | $603,000 | — |
| 2014 | 2014-06-30 | −$1.1M | — | — |
Protagenic Therapeutics, Inc.\new quarterly net income
Q2.11
Q3.11
Q2.11
Q3.11
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$963,616 | $4.1M | — |
| Q4 2026 | 2026-03-31 | $5.1M | $6.5M | — |
| Q3 2026 | 2025-12-31 | $2.2M | $3.1M | — |
| Q2 2026 | 2025-09-30 | −$869,496 | −$287,109 | — |
| Q1 2026 | 2025-06-30 | −$5.1M | −$4.7M | — |
| Q4 2025 | 2025-03-31 | −$1.4M | $284,289 | — |
| Q4 2024 | 2024-12-31 | −$850,287 | $825,897 | — |
| Q3 2024 | 2024-09-30 | −$582,387 | $814,239 | — |
| Q2 2024 | 2024-06-30 | −$324,355 | $885,236 | — |
| Q1 2024 | 2024-03-31 | −$1.7M | −$1.0M | — |
| Q4 2023 | 2023-12-31 | −$1.7M | −$1.1M | — |
| Q3 2023 | 2023-09-30 | −$1.4M | −$471,321 | — |
| Q2 2023 | 2023-06-30 | −$1.2M | −$542,874 | — |
| Q1 2023 | 2023-03-31 | −$718,096 | $644,013 | — |
| Q4 2022 | 2022-12-31 | −$601,374 | $289,013 | — |
| Q3 2022 | 2022-09-30 | −$925,305 | −$47,006 | — |
| Q2 2022 | 2022-06-30 | −$666,717 | $881,079 | — |
| Q1 2022 | 2022-03-31 | −$1.4M | −$155,657 | — |
| Q4 2021 | 2021-12-31 | −$890,387 | −$366,735 | — |
| Q3 2021 | 2021-09-30 | −$878,299 | $167,809 | — |
| Q2 2021 | 2021-06-30 | −$1.5M | −$1.1M | — |
| Q1 2021 | 2021-03-31 | −$1.2M | −$707,863 | — |
| Q4 2020 | 2020-12-31 | −$523,652 | $226,214 | — |
| Q3 2020 | 2020-09-30 | −$1.0M | −$922,801 | — |
| Q2 2020 | 2020-06-30 | −$480,386 | −$201,880 | — |
| Q1 2020 | 2020-03-31 | −$498,589 | $100,643 | — |
| Q4 2019 | 2019-12-31 | −$749,866 | $39,796 | — |
| Q3 2019 | 2019-09-30 | −$123,307 | $374,193 | — |
| Q2 2019 | 2019-06-30 | −$278,506 | $393,704 | — |
| Q1 2019 | 2019-03-31 | −$599,232 | −$1,073 | — |
| Q4 2018 | 2018-12-31 | −$789,662 | −$93,538 | — |
| Q3 2018 | 2018-09-30 | −$497,500 | −$42,933 | — |
| Q2 2018 | 2018-06-30 | −$672,210 | −$221,118 | — |
| Q1 2018 | 2018-03-31 | −$598,159 | $59,694 | — |
| Q4 2017 | 2017-12-31 | −$696,124 | −$140,047 | — |
| Q3 2017 | 2017-09-30 | −$454,567 | $909 | — |
| Q2 2017 | 2017-06-30 | −$451,092 | $73,396 | — |
| Q1 2017 | 2017-03-31 | −$657,853 | $81,932 | — |
| Q4 2016 | 2016-12-31 | −$556,077 | −$398,077 | — |
| Q3 2016 | 2016-09-30 | −$455,476 | −$15,999 | — |
| Q2 2016 | 2016-06-30 | −$524,488 | −$415,369 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$739,785 | −$701,994 | — |
| Q4 2015 | 2015-12-31 | −$158,000 | −$25,000 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$439,477 | −$327,477 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | −$109,119 | −$14,119 | — |
| Q3 2015 | 2015-03-31 | −$37,791 | $332,209 | — |
| Q2 2015 | 2014-12-31 | −$133,000 | $87,000 | — |
| Q1 2015 | 2014-09-30 | −$112,000 | $282,000 | — |
| Q4 2014 | 2014-06-30 | −$95,000 | — | — |
| Q3 2014 | 2014-03-31 | −$370,000 | — | — |
| Q2 2014 | 2013-12-31 | −$220,000 | — | — |
| Q1 2014 | 2013-09-30 | −$394,000 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | −$4.5M | −$886,000 | — |
| Q2 2011 · Jun 30 | 2011-06-30 | −$6.2M | −$1.7M | — |
| Q3 2011 · Sep 30 | 2010-09-30 | −$3.6M | — | — |
| Q2 2011 · Jun 30 | 2010-06-30 | −$4.5M | — | — |
Protagenic Therapeutics, Inc.\new net income trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's net income increased from −$1.1M to $1.4M, a change of $2.4M. The latest reported quarter, Q1 2027, shows −$963,616.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗